Aurinia Accounts Payable vs Non Current Liabilities Total Analysis
AUPH Stock | USD 8.85 0.14 1.61% |
Aurinia Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aurinia Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aurinia Pharmaceuticals is a good investment. Please check the relationship between Aurinia Pharmaceuticals Accounts Payable and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.
Accounts Payable vs Non Current Liabilities Total
Accounts Payable vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aurinia Pharmaceuticals Accounts Payable account and Non Current Liabilities Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Aurinia Pharmaceuticals' Accounts Payable and Non Current Liabilities Total is 0.48. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Aurinia Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Aurinia Pharmaceuticals' Accounts Payable and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Aurinia Pharmaceuticals are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Accounts Payable i.e., Aurinia Pharmaceuticals' Accounts Payable and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents Aurinia Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aurinia Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Non Current Liabilities Total
Most indicators from Aurinia Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Enterprise Value is estimated to increase to about 1.5 B, while Tax Provision is projected to decrease to under 670.6 K.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 225.2M | 239.8M | 253.1M | 265.7M | Cost Of Revenue | 1.1M | 5.7M | 14.1M | 7.6M |
Aurinia Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Aurinia Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aurinia Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.7M | 463.7M | 543.4M | 470.9M | 548.1M | 575.5M | |
Other Current Liab | 118K | 27.8M | 33.8M | 37.4M | 36.2M | 38.0M | |
Total Current Liabilities | 11.3M | 32.0M | 40.6M | 46.1M | 77.2M | 81.0M | |
Total Stockholder Equity | 273.5M | 407.8M | 479.1M | 405.4M | 378.0M | 396.9M | |
Property Plant And Equipment Net | 93K | 10.3M | 9.8M | 8.6M | 116.6M | 122.4M | |
Net Debt | (306.0M) | (263.9M) | (223.2M) | (86.1M) | 48.7M | 51.2M | |
Retained Earnings | (539.8M) | (575.2M) | (756.1M) | (864.3M) | (942.3M) | (895.2M) | |
Accounts Payable | 4.2M | 2.6M | 3.9M | 3.1M | 4.3M | 3.3M | |
Non Current Assets Total | 11.5M | 44.2M | 30.0M | 28.3M | 123.3M | 129.4M | |
Net Receivables | 368K | 1.0M | 15.4M | 13.5M | 24.1M | 25.3M | |
Common Stock Shares Outstanding | 93.0M | 118.5M | 129.4M | 141.9M | 143.2M | 150.4M | |
Liabilities And Stockholders Equity | 326.7M | 463.7M | 543.4M | 470.9M | 548.1M | 575.5M | |
Non Current Liabilities Total | 41.9M | 23.9M | 23.6M | 19.3M | 92.9M | 97.6M | |
Other Current Assets | 8.8M | 7.2M | 12.5M | 14.9M | 10.5M | 11.0M | |
Other Stockholder Equity | 23.7M | 39.4M | 59.0M | 85.5M | 120.8M | 66.4M | |
Total Liab | 53.2M | 55.9M | 64.3M | 65.4M | 170.1M | 178.6M | |
Property Plant And Equipment Gross | 93K | 10.3M | 9.8M | 8.6M | 118.5M | 124.4M | |
Total Current Assets | 315.1M | 419.4M | 513.3M | 442.5M | 424.8M | 446.0M | |
Short Term Debt | 6.9M | 1.6M | 2.1M | 1.9M | 31.2M | 32.8M | |
Intangible Assets | 11.2M | 9.3M | 8.4M | 6.4M | 5.0M | 7.0M | |
Cash | 306.0M | 272.4M | 231.9M | 94.2M | 48.9M | 66.4M | |
Non Currrent Assets Other | 209K | 247K | 11.8M | 13.3M | 1.5M | 2.9M | |
Cash And Short Term Investments | 306.0M | 398.3M | 466.1M | 389.4M | 350.5M | 368.0M | |
Other Liab | 14.4M | 16.3M | 16.0M | 12.2M | 14.0M | 7.3M | |
Net Tangible Assets | 289.7M | 398.4M | 470.7M | 399.0M | 458.9M | 481.8M | |
Other Assets | 209K | 5.7M | 11.8M | 13.3M | 15.3M | 16.1M | |
Common Stock Total Equity | 504.7M | 790.5M | 944.3M | 1.2B | 1.4B | 1.4B | |
Common Stock | 790.5M | 944.3M | 1.2B | 1.2B | 1.2B | 1.3B | |
Property Plant Equipment | 93K | 4.8M | 9.8M | 8.6M | 7.7M | 8.1M | |
Capital Surpluse | 24.7M | 23.7M | 39.4M | 59.0M | 67.9M | 71.3M | |
Non Current Liabilities Other | 12.3M | 1.6M | 16.0M | 12.2M | 10.9M | 8.8M | |
Net Invested Capital | 273.5M | 407.8M | 479.1M | 405.4M | 378.0M | 349.2M |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.